With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)
Canadian Hematology Today · 2022
DOI: 10.58931/cht.2022.1215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Versha Banerji. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
The treatment paradigm shift in CLL has uprooted many clinicians’ standard practices. Previously, treatment largely depended on age, organ function and “fitness” based on clinical trials which used CIRS (cumulative illness rating scale) scores. Today, as a hematologist who mainly treats patients with CLL, treatment strategies are more complex and multi-factorial. Treatments are based on molecular profiling, which aids in the identification of lower-risk patients for time-limited treatment options versus higher-risk patients (IGVH unmutated, del 17p or TP534 ) who benefit from continuous therapies. The highest-risk patients can be identified using a staging system for CLL known as the CLL-International Prognostic Index (CLL-IPI). However, increased CIRS scores are prognostic for poor outcomes independent of the CLL-IPI. As a result, selecting the right treatment for the right individual has never been more important, especially in the era of novel therapeutics. This treatment selection decision pathway includes understanding both patient factors and medical factors that may influence patient outcomes.
Zitieren
APA
Banerji, V. (2022). With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL). Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1215
Vancouver
Banerji V. With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL). Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1215
BibTeX
@article{Banerji2022,
author = {Banerji, Versha},
title = {With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)},
journal = {Canadian Hematology Today},
year = {2022},
doi = {10.58931/cht.2022.1215}
}
EUVIMED